Company nabs maintenance therapy use, but problems on breast cancer trial.
AZ hopes data will boost sales of its Farxiga.
FDA rejects blood potassium drug for second time.
UK firm lays down the gauntlet in the PARP inhibitor battle.
International initiative helps countries focus on best policies for overcoming diabetes.
UK pharma also gets $130m payment from Valeant.
But trial in patients in early stage of the disease continues.